{"id":30760,"date":"2025-01-07T16:33:30","date_gmt":"2025-01-07T11:03:30","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30760"},"modified":"2025-01-07T16:33:32","modified_gmt":"2025-01-07T11:03:32","slug":"pharma-news-for-chimerix-verastem-capricor","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-chimerix-verastem-capricor","title":{"rendered":"Chimerix Submits Dordaviprone NDA for Accelerated Approval in Recurrent H3 K27M-Mutant Diffuse Glioma to FDA; NMD Pharma\u2019s NMD670 Receives FDA Orphan Drug Designation for Charcot-Marie-Tooth Disease; Verastem\u2019s Avutometinib NDA Accepted for KRAS Mutant Ovarian Cancer; Capricor Submits BLA for Deramiocel in Duchenne Muscular Dystrophy; Axsome Completes Phase III Trial of AXS-05 for Alzheimer\u2019s Agitation"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f77eb4eed60\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f77eb4eed60\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-chimerix-verastem-capricor\/#Chimerix_Submits_Dordaviprone_NDA_for_Accelerated_Approval_to_FDA_for_Recurrent_H3_K27M-Mutant_Diffuse_Glioma\" >Chimerix Submits Dordaviprone NDA for Accelerated Approval to FDA for Recurrent H3 K27M-Mutant Diffuse Glioma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-chimerix-verastem-capricor\/#NMD_Pharma_Receives_FDA_Orphan_Drug_Designation_for_NMD670_in_Charcot-Marie-Tooth_Disease\" >NMD Pharma Receives FDA Orphan Drug Designation for NMD670 in Charcot-Marie-Tooth Disease<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-chimerix-verastem-capricor\/#Verastem_Oncology_Announces_FDA_Acceptance_and_Priority_Review_of_Avutometinib_and_Defactinib_for_KRAS_Mutant_Low-Grade_Serous_Ovarian_Cancer\" >Verastem Oncology Announces FDA Acceptance and Priority Review of Avutometinib and Defactinib for KRAS Mutant Low-Grade Serous Ovarian Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-chimerix-verastem-capricor\/#Capricor_Therapeutics_Submits_Biologics_License_Application_for_Deramiocel_in_Duchenne_Muscular_Dystrophy\" >Capricor Therapeutics Submits Biologics License Application for Deramiocel in Duchenne Muscular Dystrophy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-chimerix-verastem-capricor\/#Axsome_Therapeutics_Completes_Phase_III_Clinical_Program_of_AXS-05_for_Alzheimers_Disease_Agitation\" >Axsome Therapeutics Completes Phase III Clinical Program of AXS-05 for Alzheimer\u2019s Disease Agitation<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-chimerix-submits-dordaviprone-nda-for-accelerated-approval-to-fda-for-recurrent-h3-k27m-mutant-diffuse-glioma\"><span class=\"ez-toc-section\" id=\"Chimerix_Submits_Dordaviprone_NDA_for_Accelerated_Approval_to_FDA_for_Recurrent_H3_K27M-Mutant_Diffuse_Glioma\"><\/span>Chimerix Submits Dordaviprone NDA for Accelerated Approval to FDA for Recurrent H3 K27M-Mutant Diffuse Glioma<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Chimerix announced the submission of a NDA to the FDA for dordaviprone. The application seeks accelerated approval for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/glioma-market\">treatment of recurrent H3 K27M-mutant diffuse glioma<\/a>, a rare and aggressive brain tumor. If approved, dordaviprone could become a pivotal option for patients in the United States facing this challenging diagnosis. Chimerix has also requested Priority Review, which could set a Prescription Drug User Fee Act (PDUFA) action date in the third quarter of 2025.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThis NDA submission marks a pivotal moment for Chimerix in our mission to bring this potentially life-altering drug to patients diagnosed with recurrent H3 K27M-mutant diffuse glioma,\u201d said Mike Andriole, Chief Executive Officer of Chimerix. \u201cWith this submission, we now turn our attention to preparing for potential commercial launch in the U.S. next year. To maximize availability and access of dordaviprone at launch, we have enhanced our commercial capabilities across multiple functions, including market access, distribution, reimbursement, patient services, marketing, and commercial operations, all supported by a robust manufacturing and quality management system.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>To support the development and launch of dordaviprone, Chimerix has secured a $30 million credit facility with Silicon Valley Bank (SVB), a division of First-Citizens Bank. This facility provides access to additional capital during the upcoming investment cycle and ensures the company is well-positioned for the potential launch. \u201cWe also entered into a credit facility of up to $30 million with Silicon Valley Bank, providing access to additional capital during this critical investment cycle and helping ensure dordaviprone availability to as many patients as possible, as quickly as possible, if approved,\u201d added Michelle LaSpaluto, Chief Financial Officer of Chimerix.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Dordaviprone has received Rare Pediatric Disease Designation for H3 K27M-mutant glioma, further underscoring its potential impact on a vulnerable patient population. The company has also applied for a Rare Pediatric Disease Priority Review Voucher (PRV) as part of the NDA submission. With the robust support of strategic partnerships and enhanced operational readiness, Chimerix is committed to bringing dordaviprone to market and improving outcomes for patients facing this devastating disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-nmd-pharma-receives-fda-orphan-drug-designation-for-nmd670-in-charcot-marie-tooth-disease\"><span class=\"ez-toc-section\" id=\"NMD_Pharma_Receives_FDA_Orphan_Drug_Designation_for_NMD670_in_Charcot-Marie-Tooth_Disease\"><\/span>NMD Pharma Receives FDA Orphan Drug Designation for NMD670 in Charcot-Marie-Tooth Disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>NMD Pharma A\/S, announced that the FDA has granted Orphan Drug Designation (ODD) for NMD670, its skeletal muscle-specific ClC-1 inhibitor, for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/charcot-marie-tooth-disease-market\">treatment of Charcot-Marie-Tooth disease (CMT)<\/a>. This is the second ODD for NMD670, which previously received the designation for generalized myasthenia gravis (gMG) in 2022.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>CMT, a hereditary neuropathy affecting approximately 136,000 individuals in the U.S. and over 3 million worldwide, is characterized by muscle weakness, atrophy, fatigue, and sensory deficits that severely impact quality of life. With no approved therapies available, NMD670 aims to address these unmet needs by targeting muscle weakness and fatigue associated with the disease. \u201cThis designation underscores the urgent need for effective treatments and highlights the therapeutic potential of our ClC-1 inhibitor approach,\u201d said Thomas Holm Pedersen, CEO of NMD Pharma.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>NMD670 is currently being evaluated in the SYNAPSE-CMT Phase II clinical trial, which began in November 2024. The trial involves 80 adult patients with genetically confirmed CMT Type 1 or Type 2 subtypes, testing a twice-daily oral dose over 21 days across sites in the U.S. and Europe. Additional information and trial details can be found under identifier NCT06482437 at clinicaltrials.gov or by contacting NMD Pharma.<\/p>\n\n\n\n<p>In addition to CMT, NMD Pharma is advancing NMD670 through three global trials targeting rare neuromuscular diseases, including a Phase II study for spinal muscular atrophy (SMA) Type 3 and a Phase IIb study in gMG. Data readouts from these studies are expected between the second half of 2025 and the first half of 2026.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-verastem-oncology-announces-fda-acceptance-and-priority-review-of-avutometinib-and-defactinib-for-kras-mutant-low-grade-serous-ovarian-cancer\"><span class=\"ez-toc-section\" id=\"Verastem_Oncology_Announces_FDA_Acceptance_and_Priority_Review_of_Avutometinib_and_Defactinib_for_KRAS_Mutant_Low-Grade_Serous_Ovarian_Cancer\"><\/span>Verastem Oncology Announces FDA Acceptance and Priority Review of Avutometinib and Defactinib for KRAS Mutant Low-Grade Serous Ovarian Cancer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Verastem Oncology announced that the FDA has accepted the New Drug Application (NDA) for avutometinib, a RAF\/MEK clamp, combined with defactinib, a FAK inhibitor, for <a href=\"https:\/\/www.delveinsight.com\/report-store\/ovarian-cancer-market\">the treatment of recurrent low-grade serous ovarian cancer (LGSOC) with KRAS mutations<\/a>. The NDA, granted Priority Review, has a PDUFA action date of June 30, 2025. No advisory committee meeting is planned for this application.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThis marks a pivotal moment for patients with recurrent KRAS mutant LGSOC, a condition lacking approved treatments,\u201d said Dan Paterson, CEO of Verastem Oncology. \u201cWe\u2019re preparing for a potential commercial launch in mid-2025 and are committed to addressing this overlooked disease.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The submission was based on results from the Phase II RAMP 201 trial, presented at the 2024 IGCS Annual Meeting, which showed durable responses and good tolerability in patients treated with the avutometinib-defactinib combination. Supportive data from the FRAME Phase I trial were also included.<\/p>\n\n\n\n<p>To expand on this progress, Verastem is enrolling patients in the Phase III RAMP 301 trial, which will serve as a confirmatory study and potentially support an indication for recurrent LGSOC regardless of KRAS mutation status.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-capricor-therapeutics-submits-biologics-license-application-for-deramiocel-in-duchenne-muscular-dystrophy\"><span class=\"ez-toc-section\" id=\"Capricor_Therapeutics_Submits_Biologics_License_Application_for_Deramiocel_in_Duchenne_Muscular_Dystrophy\"><\/span>Capricor Therapeutics Submits Biologics License Application for Deramiocel in Duchenne Muscular Dystrophy<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Capricor Therapeutics has completed the submission of its Biologics License Application (BLA) to the FDA for full approval of deramiocel, <a href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-market\">an investigational cell therapy for Duchenne muscular dystrophy (DMD) cardiomyopathy<\/a>. The BLA is supported by data from the Phase II HOPE-2 trials and natural history comparisons, demonstrating deramiocel\u2019s potential to attenuate DMD-related cardiac issues.<\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<p><em>\u201cThis BLA submission is a milestone for Capricor and the DMD community, bringing us closer to delivering a transformational therapy to patients,\u201d said Linda Marb\u00e1n, Ph.D., CEO of Capricor. \u201cWe are eager to collaborate with the FDA during the review process to advance this therapy toward approval.\u201d<\/em><\/p>\n<\/div>\n<\/div>\n\n\n\n<p>Capricor has requested Priority Review, which could reduce the review timeline from 10 to 6 months. A $10 million milestone payment from Nippon Shinyaku Co., Ltd., under their U.S. Commercialization and Distribution Agreement, is tied to this achievement.<\/p>\n\n\n\n<p>Deramiocel holds Orphan Drug Designation from the FDA and EMA, RMAT Designation in the U.S., and ATMP Designation in Europe. FDA approval could also make Capricor eligible for a Priority Review Voucher, given the therapy\u2019s rare pediatric disease designation.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-axsome-therapeutics-completes-phase-iii-clinical-program-of-axs-05-for-alzheimer-s-disease-agitation\"><span class=\"ez-toc-section\" id=\"Axsome_Therapeutics_Completes_Phase_III_Clinical_Program_of_AXS-05_for_Alzheimers_Disease_Agitation\"><\/span>Axsome Therapeutics Completes Phase III Clinical Program of AXS-05 for Alzheimer\u2019s Disease Agitation<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Axsome Therapeutics has announced the successful completion of its Phase III clinical program evaluating AXS-05 (dextromethorphan-bupropion) for <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\">treating agitation associated with Alzheimer\u2019s disease.<\/a> The program included multiple trials, with the ACCORD-2 trial meeting its primary endpoint by significantly delaying the time to relapse of agitation compared to placebo. Patients receiving AXS-05 experienced a 3.6-fold lower risk of relapse (hazard ratio: 0.276, p=0.001). The key secondary endpoints were also met, with AXS-05 reducing the relapse rate (8.4% for AXS-05 vs. 28.6% for placebo, p=0.001) and preventing worsening of disease severity. These results reinforce the therapeutic potential of AXS-05 in addressing agitation, a highly distressing symptom for Alzheimer\u2019s patients and their caregivers.<\/p>\n\n\n\n<p>The ADVANCE-2 trial, another Phase III study, showed numerical improvements favoring AXS-05 over placebo across most endpoints, although the primary endpoint of CMAI score reduction did not achieve statistical significance. Despite this, the trial contributed valuable safety data. In both short-term and long-term studies, AXS-05 was well-tolerated, with no increased risks of sedation, cognitive decline, or mortality. Adverse events were minimal and included dizziness and headache. Long-term safety assessments demonstrated consistent tolerability over extended use, with over 300 patients treated for at least six months and over 100 for at least 12 months.<\/p>\n\n\n\n<p>Axsome plans to submit a New Drug Application (NDA) for AXS-05 to the FDA in the second half of 2025. This follows the drug\u2019s Breakthrough Therapy designation for Alzheimer\u2019s disease agitation, granted in 2020 based on earlier positive trial results. The regulatory submission will leverage data from four Phase III trials, including three that demonstrated statistically significant efficacy. According to Jeffrey Cummings, MD, ScD, the robust clinical data highlight AXS-05\u2019s potential to address a significant unmet need in Alzheimer\u2019s disease care by reducing agitation and improving disease severity.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>CEO Herriot Tabuteau, MD, expressed optimism about the drug\u2019s ability to provide meaningful benefits to patients and their families. The company aims to bring this innovative therapy to market, marking a crucial step toward improving the quality of life for those affected by Alzheimer\u2019s disease agitation. With its comprehensive clinical evidence and favorable safety profile, AXS-05 has the potential to become a pivotal treatment for this challenging condition.<\/em><\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>Chimerix Submits Dordaviprone NDA for Accelerated Approval to FDA for Recurrent H3 K27M-Mutant Diffuse Glioma Chimerix announced the submission of a NDA to the FDA for dordaviprone. The application seeks accelerated approval for the treatment of recurrent H3 K27M-mutant diffuse glioma, a rare and aggressive brain tumor. If approved, dordaviprone could become a pivotal option [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":30763,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[13035,72,18819,204,1796,218,263,17569,21761,349,420,444,639,5789],"industry":[17225],"therapeutic_areas":[17238,17245,17228],"class_list":["post-30760","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alzheimers-2","tag-alzheimers-disease","tag-charcot-marie-tooth-disease-market","tag-delveinsight","tag-duchenne-muscular-dystrophy","tag-duchenne-muscular-dystrophy-dmd","tag-genetic-disorders","tag-glioma","tag-glioma-market","tag-latest-pharma-news","tag-news","tag-ovarian-cancer","tag-pharma-news","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Chimerix, Verastem, Capricor<\/title>\n<meta name=\"description\" content=\"Chimerix\u2019s Dordaviprone, NMD Pharma\u2019s NMD670, Verastem\u2019s Avutometinib, Capricor\u2019s Deramiocel BLA, Axsome\u2019s AXS-05 Phase III Trial\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-chimerix-verastem-capricor\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Chimerix, Verastem, Capricor\" \/>\n<meta property=\"og:description\" content=\"Chimerix\u2019s Dordaviprone, NMD Pharma\u2019s NMD670, Verastem\u2019s Avutometinib, Capricor\u2019s Deramiocel BLA, Axsome\u2019s AXS-05 Phase III Trial\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-chimerix-verastem-capricor\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-07T11:03:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-07T11:03:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/07163234\/pharma-news-for-chimerix-verastem-capricor.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Chimerix, Verastem, Capricor","description":"Chimerix\u2019s Dordaviprone, NMD Pharma\u2019s NMD670, Verastem\u2019s Avutometinib, Capricor\u2019s Deramiocel BLA, Axsome\u2019s AXS-05 Phase III Trial","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-chimerix-verastem-capricor","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Chimerix, Verastem, Capricor","og_description":"Chimerix\u2019s Dordaviprone, NMD Pharma\u2019s NMD670, Verastem\u2019s Avutometinib, Capricor\u2019s Deramiocel BLA, Axsome\u2019s AXS-05 Phase III Trial","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-chimerix-verastem-capricor","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-01-07T11:03:30+00:00","article_modified_time":"2025-01-07T11:03:32+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/07163234\/pharma-news-for-chimerix-verastem-capricor.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-chimerix-verastem-capricor","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-chimerix-verastem-capricor","name":"Pharma News | Chimerix, Verastem, Capricor","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-chimerix-verastem-capricor#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-chimerix-verastem-capricor#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/07163234\/pharma-news-for-chimerix-verastem-capricor.png","datePublished":"2025-01-07T11:03:30+00:00","dateModified":"2025-01-07T11:03:32+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Chimerix\u2019s Dordaviprone, NMD Pharma\u2019s NMD670, Verastem\u2019s Avutometinib, Capricor\u2019s Deramiocel BLA, Axsome\u2019s AXS-05 Phase III Trial","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-chimerix-verastem-capricor"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-chimerix-verastem-capricor#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/07163234\/pharma-news-for-chimerix-verastem-capricor.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/07163234\/pharma-news-for-chimerix-verastem-capricor.png","width":772,"height":482,"caption":"pharma-news-for-chimerix-verastem-capricor"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/07163234\/pharma-news-for-chimerix-verastem-capricor-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Charcot-Marie-Tooth Disease Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Duchenne muscular dystrophy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Duchenne muscular dystrophy (DMD)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Genetic Disorders<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Glioma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Glioma Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ovarian Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alzheimer\u2019s<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Charcot-Marie-Tooth Disease Market<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Duchenne muscular dystrophy<\/span>","<span class=\"advgb-post-tax-term\">Duchenne muscular dystrophy (DMD)<\/span>","<span class=\"advgb-post-tax-term\">Genetic Disorders<\/span>","<span class=\"advgb-post-tax-term\">Glioma<\/span>","<span class=\"advgb-post-tax-term\">Glioma Market<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Ovarian Cancer<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Jan 7, 2025","modified":"Updated on Jan 7, 2025"},"absolute_dates_time":{"created":"Posted on Jan 7, 2025 4:33 pm","modified":"Updated on Jan 7, 2025 4:33 pm"},"featured_img_caption":"pharma-news-for-chimerix-verastem-capricor \n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30760"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30760\/revisions"}],"predecessor-version":[{"id":30764,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30760\/revisions\/30764"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30763"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30760"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30760"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}